"I'm just being pessimistic (or conservative) based upon past experience with Neuren."
Just on the above Kjt - I can understand that comment historically - but Neuren is a completely different company now since the successful Phase 3 trial for Rett Syndrome.
It used to be a sell on the news and buy on the rumour type company.... as are many not yet established companies! Now, it is a buy on news and hold in between company.....
The company has been totally re-rated as a result of the December 2021 news - it is now in the target zone for sophisticated investers. There used to be a saying in my industry "No one ever gets fired for buying Microsoft"... (Though, that is changing/changed)... I think now - you could say "No one ever gets fired for buying Neuren" ... as it now ticks so many boxes that it did not previously.
You look at Neuren now and the risks involved are almost completely removed. It's products are safe and they work. It is here for the foreseeable future owning treatments for many neurological disorders.
NEU Price at posting:
$4.35 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)